# Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

> **NCT01701856** · PHASE4 · TERMINATED · sponsor: **Claudio Gobbi** · enrollment: 5 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Interferon beta-1b

## Key facts

- **NCT ID:** NCT01701856
- **Lead sponsor:** Claudio Gobbi
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Problems to recruit the needed number of patients in the planned time
- **Last updated:** 2014-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01701856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01701856, "Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01701856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*